Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
526 participants
INTERVENTIONAL
2003-08-31
2004-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A,1
rFSH + rLH arm
recombinant luteinizing hormone (Luveris)
75 iu/day form cycle day 6
A,2
rFSH alone
recombinant follicle stimulating hormone (Gonal-f)
rFSH 150 iu/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
recombinant luteinizing hormone (Luveris)
75 iu/day form cycle day 6
recombinant follicle stimulating hormone (Gonal-f)
rFSH 150 iu/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infertility treatable by IVF or ICSI
* Regular cycles
Exclusion Criteria
21 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regionshospitalet Viborg, Skive
OTHER
Karolinska University Hospital
OTHER
Helse Fonna
OTHER
Turku Hospital
UNKNOWN
Odense University Hospital
OTHER
Herlev Hospital
OTHER
Holbaek Sygehus
OTHER
Hvidovre University Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anders N Andersen, professor
Role: PRINCIPAL_INVESTIGATOR
Fertility Clinic Rigshospitalet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anders Nyboe Andersen
Copenhagen, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
NyboeAndersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsboll S, Rasmussen PE, Lindenberg S, Bredkjaer HE, Meinertz H; Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod. 2008 Feb;23(2):427-34. doi: 10.1093/humrep/dem317. Epub 2007 Nov 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KF02-035/03
Identifier Type: -
Identifier Source: org_study_id